Comparative Pharmacology
Head-to-head clinical analysis: DIMENHYDRINATE versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMENHYDRINATE versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
DIMENHYDRINATE vs PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimenhydrinate is a histamine H1 antagonist with central anticholinergic activity. It acts by blocking H1 receptors in the brain's vomiting center and inhibiting vestibular stimulation. It also has anticholinergic effects by binding to muscarinic receptors, reducing motion sickness.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative. Dextromethorphan is a cough suppressant that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
50-100 mg orally or intramuscularly every 4-6 hours as needed; maximum 400 mg per day. For motion sickness, 50-100 mg 30 minutes before travel.
For cough and upper respiratory symptoms: 5 mL (containing promethazine hydrochloride 6.25 mg and dextromethorphan hydrobromide 15 mg) orally every 4 to 6 hours, not to exceed 30 mL in 24 hours.
None Documented
None Documented
Clinical Note
moderateDimenhydrinate + Venlafaxine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine."
Clinical Note
moderateDimenhydrinate + Nefazodone
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone."
Clinical Note
moderateDimenhydrinate + Stiripentol
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is 5-10 hours in adults, longer in elderly or hepatic impairment (up to 15 hours).
Promethazine: 10-19 hours (mean 12 hours). Dextromethorphan: extensive metabolizers (CYP2D6) 3-5 hours; poor metabolizers 20-30 hours. Clinical context: accumulation with repeated dosing, especially in poor metabolizers.
Primarily renal, with 60-80% of the dose excreted unchanged in urine; minor biliary/fecal elimination accounts for <10%.
Promethazine: primarily hepatic metabolism, renal excretion of metabolites (~70%, <1% unchanged); fecal excretion (20-30%). Dextromethorphan: hepatic metabolism, renal excretion of metabolites and <1% unchanged drug.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic
Dimenhydrinate + Clomipramine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine."